Table 3 Maternal data at delivery: “on-diet”: 31 singleton deliveries and 3 twin deliveries
Case | sCr mg/dL (EPI-GFR mL/min) | Stage CKD | PtU g/24 h | Pt/Alb (g/dL) | Weight gain | Hospitalization | sCr mg/dL (EPI-GFR mL/min) 3 months | PtU g/die Serum Alb g/dl 3 months |
|---|---|---|---|---|---|---|---|---|
1 | 1.8 (36) | 3 | 6.2 | 4.8/1.9 | 9 (13.4 %) | 95 | 2.0 (45) | 3/2.5 |
2 | 1.8 (36) | 3 | 5.6 | 5.7/2.8 | 11 (20 %) | 73 | 1.9 (40) | 4/3 |
3 | 3.7 (16) | 4 | 2.6 | 6.3/3.6 | 9 (16 %) | 55 | 4.5 | 0.3/3.6 |
4 | 2 (31) | 3 | 1.9 | 5.6/2.9 | 9 (18 %) | 47 | 2.1 (21) | 1.5/3.1 |
5 | 0.7 (115) | 1 | 3.4 | 4.8/2.9 | 14 (21.5 %) | 123 | - | - |
6 | 2.9 (20) | 4 | 2.0 | 6.2/2.9 | 10 (21.7 %) | 80 | 2.8 (25) | 1.5/3.5 |
7 | 5 (11) | 5 | 17.3 | 4.2/1.8 | 16 (25 %) | 93 | 4.3 (19) | 5/3.1 |
8 | 0.6 (116) | 1 | 2.1 | 5.0/2.4 | 10 (20 %) | 30 | 0.8 (120) | 4/3.2 |
9 | 1.3 (54) | 3 | 3.6 | 5.3/2.8 | 8 (12 %) | 84 | 1.2 (64) | 1.3/- |
10 | 0.5 (140) | 1 | 2.9 | 5.4/2.7 | 11 (17 %) | 63 | 0.7 (125.1) | 6.2/2.8 |
11 | 1.8 (35) | 3 | 5.4 | 5.4/2.8 | 5 (7 %) | 99 | 1.7 (52.9) | 6.8/3.8 |
12 | 0.8 (99) | 1 | 5.7 | 5.5/2.7 | 10 (17.9 %) | 9 | 1.2 (60.6) | 5.7/3.2 |
13 | 1.5 (45) | 3 | 5.5 | 5.0/2.6 | 4 (7.8 %) | 28 | 2.9 (23.3) | 3.4/4 |
14 | 1 (73) | 2 | 4.7 | 4.5/2.2 | 12 (21 %) | 29 | 0.9 (82.5) | 4.4/2.2 |
15 | 1.5 (44) | 3 | 9.4 | 5.5/2.6 | 8 (14 %) | 24 | 1.9 (33.7) | 1.3/5.7 |
16 | 1 (72) | 2 | 4.4 | 6.4/2.8 | 14 (30.4 %%) | 24 | 0.9 (80.2) | 1.4/3.5 |
17 | 1.1 (65) | 2 | 2.2 | 6.0/2.9 | 11 (20.4 %) | 9 | na | na |
18 | 3.6 (15) | 4 | 3.4 | 5.8/3.2 | 12 (17.9 %) | 26 | 3.1 (18.5) | 1.3/3.2 |
19 | 0.6 (115) | 1 | 1.4 | 5.2/2.6 | 10 (14.1 %) | 16 | 0.7 (110.3) | 2.5/2.7 |
20 | 1.8 (37) | 3 | 0.8 | 6.7/3.3 | 7 (9.2 %) | 12 | 1.7 (39.1) | 1/3.9 |
21 | 1.2 (60) | 2 | 1.7 | 5.9/3.1 | 15 (23.8 %) | 8 | 1.8 (37.2) | 0.3/4.1 |
22 | 0.7 (105) | 1 | 0.9 | 5.7/2.9 | 10 (20.4 %) | 3 | 0.8 (98.7) | 0.8/4.5 |
23 | 1 (69) | 2 | 0.3 | 6.8/3.6 | 12 (22.6 %) | 4 | 1.3 (53.7) | 0.1/3.7 |
24 | 1.2 (63.2) | 2 | 0.6 | 6.7/3.6 | 6 (10 %) | 13 | 1.1 (69.5) | 0.1/4 |
25 | 0.8 (90.5) | 1 | 1.8 | 5.5/3.2 | 6 (7 %) | 7 | 0.9 (76.6) | 0.7/4.3 |
26 | 1 (75.6) | 2 | 0.8 | 6.6/3.1 | 22 (31 %) | 5 | 1.0 (74.7) | 0.8/3.3 |
27 | 0.9 (86) | 2 | 0.9 | 5.9/3.1 | 1 (1 %) | 16 | na | na |
28 | 0.5 (131.1) | 1 | 0.4 | 6.0/2.7 | −2 (−2.5 %) | 5 | 0.6 (118.9) | 0.5/4.7 |
29 | 1 (89.9) | 2 | 6.2 | 5.5/2.9 | 6 (7.9 %) | 5 | 1.0 | na |
30 | 2 (31.6) | 3 | 0.1 | 6.4/3.2 | 9 (15 %) | 22 | na | na |
31 | 2.33 (27) | 4 | 0.41 | 6.4/3.3 | 15 (22 %) | 24 | na | na |
32 (twin) | 0.7 (117) | 1 | 11.8 | 4.1/1.8 | 21 (42 %) | 76 | 0.6 (121.8) | 1.5/3.7 |
33 (twin) | 0.9 (81.4) | 2 | na | 6.1/3.3 | 3 (3.3 %) | 8 | na | na |
34 (twin) | 0.6 (120) | 1 | 0.9 | 5.6/3.0 | 24 (27.3 %) | 14 | na | na |
Summary data (singletons) | sCr 1.2 (0.5–5.0) GFR-EPI 63.2 (11.0–140.0) | 3 (1–4) | 2.2 (0.1–17.3) | Pt 5.7 (4.2–6.8) Alb 2.9 (1.8–3.6) | 10.0 (−2–22) | 24 (3–123) | sCr 1.25 (0.6–4.5) GFR-EPI 57.15 (18.5–125.1) | PtU 1.4 (0.1–6.8) Serum Alb 3.5 (2.2–5.7) |